FDA Points To Premarket Clearance For Direct-To-Consumer Genetic Tests
This article was originally published in The Tan Sheet
Executive Summary
FDA tells direct-to-consumer genetic testing company 23andMe that it should immediately stop marketing its Personal Genome Service in a strongly worded, lengthy warning letter that experts say could provide guidance across the sector. The firm says it will address the agency’s concerns.
You may also be interested in...
Personal Genome Service For Carrier Screening Emerges From 23andMe Work With FDA
Two years of conversations with FDA lead 23andMe back to the health care market with the launch of its Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA improved its customer communication and quality control.
Personal Genome Service For Carrier Screening Emerges From 23andMe Work With FDA
Two years of conversations with FDA lead 23andMe back to the health care market with the launch of its Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA improved its customer communication and quality control.
510(k) Program, Companion Dx Among Top FDA Guidance Priorities For FY 2014
CDRH says it plans to release the 510(k) program final guidance as well as the anticipated in vitro companion diagnostic final guidance next year. The device center has divided the 22 forthcoming guidance documents into an “A-list” and a “B-list,” based on its priorities and allocated resources.